MiMedx Group Stock - Analyst and consensus snapshot after quiet news day

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 20:30 UTC. Details in the imprint.

MiMedx Group (US60251E1029) remains without new company announcements or major filings today. With no fresh catalysts from investor relations or regulators, the focus shifts to how analysts model the Nasdaq-listed regenerative medicine specialist's earnings and growth trajectory.

What current data providers show

On third-party data platforms, MiMedx Group is classified within the US pharmaceuticals and biotechnology universe, focusing on advanced wound care and regenerative biologics using placental tissue. Simply Wall St lists the company under a regenerative medicines peer group with a mid-cap profile as of 03/31/2026.

According to recent quote data, MiMedx Group shares last closed at $3.67 on Nasdaq on 06/18/2026, implying a modest daily gain of 1.66% on that date. TradingKey also reports that after-hours trading on the same day showed no material price change, with volume characterized as moderate for the stock.

Analyst estimates and sentiment today

Consensus snapshots compiled by independent platforms indicate that analysts expect MiMedx Group to grow revenue over the coming years from its base in advanced wound care and musculoskeletal applications, though detailed per-share estimates vary by provider. Some models emphasize margin expansion as the company scales manufacturing and distribution.

Analyst sentiment, where published, generally sits in the neutral-to-positive range, with a mix of Hold and Buy ratings and limited formal Sell calls reported on major data aggregators. Overall, the shares trade at valuation multiples that reflect both the company’s growth prospects and the regulatory and reimbursement risks typical for US medtech and biotech names.

How MiMedx Group makes money

MiMedx Group generates revenue primarily by developing, manufacturing and marketing placental tissue allografts that are used in advanced wound care, surgical recovery and orthopedic applications. The portfolio centers on allograft products derived from human placental tissue that support tissue repair and reduce inflammation in chronic and acute wounds.

Where the stock trades today

The shares of MiMedx Group (US60251E1029) last traded on Nasdaq at $3.67 as of 06/18/2026, 16:00 ET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.